Management of Hospital-Acquired Pneumonia
For a hospitalized patient who develops pneumonia, immediately stratify by mortality risk and MRSA risk factors, then initiate empiric antibiotics within 1 hour: use piperacillin-tazobactam 4.5g IV q6h OR cefepime 2g IV q8h for low-risk patients without MRSA factors; add vancomycin 15mg/kg IV q8-12h (target trough 15-20 mg/mL) for high-risk patients or those with MRSA risk factors. 1
Workup Algorithm
Clinical Assessment
Identify mortality risk factors:
- Need for ventilatory support due to pneumonia
- Septic shock 1
Identify MRSA risk factors:
- IV antibiotic use within prior 90 days
- Unit where >20% of S. aureus isolates are methicillin-resistant (or prevalence unknown)
- Prior MRSA detection by culture or screening 1
Diagnostic Testing
- Obtain respiratory cultures BEFORE starting antibiotics (critical for subsequent de-escalation)
- Gram stain of respiratory specimen (if numerous gram-negative bacilli present, consider dual antipseudomonal coverage) 1
- Blood cultures
- Chest imaging to confirm pneumonia
Review Local Antibiogram
- Base empiric regimen on your hospital's HAP-specific antibiogram 1
- This is a strong recommendation from IDSA/ATS guidelines
Empiric Antibiotic Selection
Low-Risk Patients (No MRSA Risk + No High Mortality Risk)
Choose ONE of the following:
- Piperacillin-tazobactam 4.5g IV q6h
- Cefepime 2g IV q8h
- Levofloxacin 750mg IV daily
- Imipenem 500mg IV q6h
- Meropenem 1g IV q8h 1
Rationale: These provide MSSA and gram-negative coverage. Recent network meta-analysis suggests piperacillin-tazobactam may be among the most effective in reducing treatment failure (RR 0.65 vs cephalosporins) 2.
Intermediate-Risk Patients (MRSA Risk BUT No High Mortality Risk)
Same single-agent options as above PLUS:
- Vancomycin 15mg/kg IV q8-12h (target trough 15-20 mg/mL)
- OR Linezolid 600mg IV q12h 1
Critical point: Vancomycin or linezolid are the only recommended MRSA agents (strong recommendation) 1.
High-Risk Patients (High Mortality Risk OR Recent IV Antibiotics Within 90 Days)
Choose TWO agents from different classes (avoid combining two β-lactams):
β-lactam options (pick one):
- Piperacillin-tazobactam 4.5g IV q6h
- Cefepime or ceftazidime 2g IV q8h
- Imipenem 500mg IV q6h
- Meropenem 1g IV q8h
Second agent (pick one):
- Levofloxacin 750mg IV daily OR Ciprofloxacin 400mg IV q8h
- Amikacin 15-20mg/kg IV daily OR Gentamicin 5-7mg/kg IV daily OR Tobramycin 5-7mg/kg IV daily
- Aztreonam 2g IV q8h
PLUS MRSA coverage:
- Vancomycin 15mg/kg IV q8-12h (consider loading dose 25-30mg/kg × 1 for severe illness)
- OR Linezolid 600mg IV q12h 1
Special Considerations
Structural Lung Disease
- If bronchiectasis or cystic fibrosis present: mandate dual antipseudomonal coverage regardless of other risk factors 1
Severe Penicillin Allergy
- If using aztreonam instead of β-lactam, must add separate MSSA coverage (aztreonam lacks gram-positive activity) 1
If MRSA Coverage Omitted
- Ensure regimen includes MSSA coverage (piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem are acceptable) 1
- For proven MSSA after cultures return, switch to oxacillin, nafcillin, or cefazolin 1
Common Pitfalls to Avoid
Delaying cultures: Obtain respiratory specimens before antibiotics whenever possible—this dramatically impacts ability to de-escalate therapy 3
Over-treating low-risk patients: The 20% MRSA threshold balances appropriate coverage against C. difficile risk, adverse effects, and resistance development 1
Under-treating high-risk patients: Recent IV antibiotics within 90 days is an absolute indication for dual gram-negative coverage 1
Ignoring local resistance patterns: Generic guidelines cannot replace your institution's antibiogram 1
Empiric MRSA coverage without indication: Recent evidence suggests empiric MRSA coverage may not reduce mortality when risk factors absent 2